Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

Ascletis Pharma's denifanstat (ASC40), an oral FASN inhibitor, achieved statistically significant and clinically meaningful improvements in a Phase III trial for moderate-to-severe acne, demonstrating a favorable safety profile. The trial showed denifanstat was significantly more effective than FDA-approved treatments like sarecycline, doxycycline, and clascoterone cream across key metrics, including treatment success and lesion reduction. These results position denifanstat as a potential first-in-class oral acne therapeutic with a unique mechanism of action, addressing the underlying cause of acne by directly inhibiting sebum production.

Analysis

Ascletis Pharma's denifanstat (ASC40), an investigational once-daily oral fatty acid synthase (FASN) inhibitor, has demonstrated highly compelling results in its Phase III clinical trial for moderate-to-severe acne. The trial met all primary, key secondary, and secondary endpoints with statistical significance (p<0.0001 for all reported efficacy endpoints) and clinical meaningfulness. Specifically, denifanstat achieved a 33.2% treatment success rate versus 14.6% for placebo, a 57.4% reduction in total lesion count compared to 35.4% for placebo, and a 63.5% reduction in inflammatory lesion count versus 43.2% for placebo at week 12. The drug also showed a 51.9% reduction in non-inflammatory lesion count compared to 28.9% for placebo. Importantly, denifanstat exhibited a favorable safety and tolerability profile, with treatment-emergent adverse event (TEAE) rates comparable to placebo; no study drug-related TEAEs exceeded 10%, and only dry skin (6.3%) and dry eye (5.9%) had incidence rates over 5%. All denifanstat-related adverse events were mild or moderate, with no grade 3/4 or serious AEs reported. Non-head-to-head comparisons suggest denifanstat's superior efficacy over existing FDA-approved treatments, demonstrating 98% and 178% greater placebo-adjusted treatment success than sarecycline and doxycycline, respectively, and 60% greater success than clascoterone cream. Denifanstat's unique mechanism, directly inhibiting sebum production and inflammation, positions it as a potential first-in-class therapeutic addressing a primary cause of acne, potentially offering better patient compliance and avoiding issues like antibiotic resistance associated with current treatments. Ascletis Pharma, which licenses denifanstat from Sagimet Biosciences Inc. (SGMT) for Greater China, plans an NMPA submission, signaling a significant step towards commercialization in a key market.

Key Decisions for Investors

• Investors should view the positive Phase III results for denifanstat as a significant de-risking event and a potential key value driver for Ascletis Pharma (1672.HK), given the drug's superior efficacy and safety profile.
• Consider the substantial market opportunity for a first-in-class oral acne treatment that addresses underlying causes with improved compliance and safety, potentially disrupting the existing treatment paradigm.
• Monitor Ascletis Pharma's upcoming regulatory submission to the China NMPA and subsequent approval process, as these are critical catalysts for realizing denifanstat's commercial potential.
• For investors in Sagimet Biosciences (SGMT), this successful Phase III trial outcome for its licensed asset could translate into future milestone payments and royalties, positively impacting its valuation.